Biotechnology company Capsida Biotherapeutics opened its gene therapy manufacturing facility in Thousand Oaks just two years after the company’s founding.

The 15,000-square-foot facility cuts out the manufacturing middleman for Capsida and will enable the company to bring products from discovery into clinical studies faster.

“Our robust process development and analytical capabilities are cornerstones of our ability to reliably produce high-quality gene therapies to meet worldwide regulatory expectations,” Rayne Waller, Capsida’s chief manufacturing officer, said in a statement. Prior to joining Capsida, Waller was with Thousand Oaks-based Amgen Inc.’s manufacturing and supply chain divisions.


Join our Membership to get the full story.

Are you a current Member? Sign In